Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Tiziana Life Sciences Ltd (TLSA)

Tiziana Life Sciences Ltd (TLSA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 72,614
  • Shares Outstanding, K 102,273
  • Annual Sales, $ 0 K
  • Annual Income, $ -23,420 K
  • 60-Month Beta 1.10
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.85
Trade TLSA with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm 0.00
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 08/19/22
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 534.12% ( -20.51%)
  • Historical Volatility 90.93%
  • IV Percentile 89%
  • IV Rank 40.82%
  • IV High 1,138.38% on 06/23/22
  • IV Low 117.36% on 01/26/22
  • Put/Call Vol Ratio 0.00
  • Today's Volume 0
  • Volume Avg (30-Day) 12
  • Put/Call OI Ratio 0.00
  • Today's Open Interest 218
  • Open Int (30-Day) 373

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/22
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.6517 +8.95%
on 06/02/22
0.9436 -24.76%
on 06/09/22
-0.0098 (-1.36%)
since 06/01/22
3-Month
0.6022 +17.90%
on 05/31/22
1.0900 -34.86%
on 04/05/22
-0.3400 (-32.38%)
since 04/01/22
52-Week
0.5301 +33.94%
on 02/24/22
2.3600 -69.92%
on 07/02/21
-1.6400 (-69.79%)
since 07/01/21

Most Recent Stories

More News
Tiziana Life Sciences Ltd. Receives Nasdaq Deficiency Notice

NEW YORK, June 17, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences (Nasdaq: TLSA) ("Tiziana" or the "Company"), a biotechnology company enabling...

TLSA : 0.7100 (-4.76%)
TILS.LN : 58.500 (+8.33%)
Tiziana Life Sciences Announces Purchase of Common Shares by Executive Chairman

NEW YORK, June 10, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd.(Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company enabling...

TILS.LN : 58.500 (+8.33%)
TLSA : 0.7100 (-4.76%)
Tiziana Life Sciences PLC (TLSA: NASDAQ) Releases Research Report: Clinical Improvements for 2nd SPMS Patient

Zacks Small-Cap Research Note By John D. Vandermosten, CFA NEW YORK, June 09, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences PLC (NASDAQ: TLSA)...

TILS.LN : 58.500 (+8.33%)
TLSA : 0.7100 (-4.76%)
Tiziana Life Sciences Announces An Interview on Clinical Improvements for 2nd SPMS Patient

NEW YORK, June 09, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences (Nasdaq: TLSA) ("Tiziana" or the "Company"), a biotechnology company enabling...

TILS.LN : 58.500 (+8.33%)
TLSA : 0.7100 (-4.76%)
Tiziana Life Sciences PLC (TLSA: NASDAQ) Clinical Improvements for 2nd SPMS Patient

Research Note Clinical Results for Second SPMS Patient NEW YORK, June 09, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences PLC (NASDAQ: TLSA)...

TILS.LN : 58.500 (+8.33%)
TLSA : 0.7100 (-4.76%)
Tiziana Life Sciences to Present at the 2022 Biotechnology Innovation Organization Annual Convention to Discuss Recent Updates to Ongoing Clinical Programs

NEW YORK, June 06, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd (NASDAQ: TLSA) ("Tiziana" or the "Company"), a clinical-stage biopharmaceutical...

TILS.LN : 58.500 (+8.33%)
TLSA : 0.7100 (-4.76%)
Tiziana Life Sciences Ltd. Announces Annual Report Filed to Regain Nasdaq Compliance

Form 20-F Filed on May 23, 2022 Following Receipt of Notice from Nasdaq Regarding Filing Deadline of its Annual Report...

TLSA : 0.7100 (-4.76%)
TILS.LN : 58.500 (+8.33%)
Tiziana Life Sciences to participate in a Fireside Chat At the B. Riley Securities 2022 Virtual Neuro & Ophthalmology Conference

NEW YORK, April 26, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd (NASDAQ: TLSA) ("Tiziana" or the "Company"), a clinical-stage biopharmaceutical...

TILS.LN : 58.500 (+8.33%)
TLSA : 0.7100 (-4.76%)
LTUM Stock Alert: Why Is Lithium Corporation Stock Up Today?

After a false report, multiple sources have confirmed Tesla is not acquiring the lithium miner

TLSA : 0.7100 (-4.76%)
LTUM : 0.2028 (+1.35%)
TWTR : 38.23 (+2.25%)
Tiziana Announces Initiation of Phase 1b Clinical Trial in Crohn’s Disease Patients to Evaluate Oral Capsules of Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody

This clinical trial, the first-ever oral immunotherapy for patients with mild-to-moderately active Crohn's Disease, is anticipated to be completed by Q4,...

TILS.LN : 58.500 (+8.33%)
TLSA : 0.7100 (-4.76%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Tiziana Life Sciences PLC is a biotechnology company. It focuses on the clinical development for the treatment of cancers, chronic inflammatory and autoimmune neurodegenerative disorders. The company's product pipeline consists of Foralumab TZLS-401 and Milciclib TZLS-201 which are in clinical stage....

See More

Key Turning Points

3rd Resistance Point 0.8300
2nd Resistance Point 0.7980
1st Resistance Point 0.7540
Last Price 0.7100
1st Support Level 0.6780
2nd Support Level 0.6460
3rd Support Level 0.6020

See More

52-Week High 2.3600
Fibonacci 61.8% 1.6610
Fibonacci 50% 1.4451
Fibonacci 38.2% 1.2291
Last Price 0.7100
52-Week Low 0.5301

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar